Why Some FDA Approvals Trigger Stock Drops Instead of Gains

An analysis of why biotech stocks sometimes fall after FDA approval due to market expectations and valuation dynamics.

Introduction

Market gradually prices in a drug's market potential throughout its entire development process. Certain regulatory and clinical milestones can trigger sharp increases in share price, reflecting the market starting to price in future commercial value. As a result, by the time the FDA PDUFA date arrives, the drug's full potential may already be priced in or even overpriced. When that happens, the FDA approval announcement becomes a trigger for “sell the news,” leading to a share price drop rather than a gain.

Timeline of Major Catalysts in a Drug’s Development Path:

IND (Investigational new drug) application
Phase 2 trial results
FDA Designations
Phase 3 trial results
NDA/BLA submission to FDA
FDA acceptance of filing & assignment of PDUFA date
FDA Advisory Committee vote
FDA PDUFA decision

1. How the Market Prices in a Drug’s Value Over Time

The pricing process often starts early. When an IND application is accepted by the FDA, it signals that the agency has cleared the drug to enter human trials. This is an important milestone indicating that the drug has officially moved from the discovery stage into clinical development, the gateway to eventual commercialization. Phase 1 safety trials and Phase 2 clinical trials are limited studies conducted in relatively small populations to assess safety and early efficacy. As one of the major re-pricing events, Phase 2 results provide the first meaningful evidence of clinical efficacy in humans based on U.S. Food and Drug Administration. Investigational New Drug (IND) Application (1). If the data is positive, the drug’s probability of success increases sharply, and the market responds accordingly.

The next development phase involves FDA designations, which represent a form of recognition by the agency and signal regulatory momentum and commercial potential. Receiving a designation such as Fast Track or Breakthrough Therapy is the first time the FDA publicly hints at a supportive regulatory stance toward the drug, according to Lyons, T. (2023). Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices (2). Because of that, designations often act as meaningful catalysts for the share price.

Then comes the final major clinical milestone: Phase 3 trial results. These are typically the data that pharmaceutical companies submit to the FDA for PDUFA review as evidence of safety and efficacy. Phase 3 readouts serve as the most influential dataset for investors attempting to interpret and predict the FDA regulatory outcome according to Biotechnology stock prices before public announcements: evidence of insider trading? Journal of Investigative Medicine, 48(2), 118–124 (3).

This is exactly the period that before the PDUFA date, when a company begins to receive unprecedented attention from the market. Most investors lack the specialized knowledge required to understand a drug’s true approval probability, let alone perform a reasonable revenue forecast. Without a sound, data-driven valuation for the drug’s potential and its associated share price, the market can easily become overheated, with investors rushing in on any news that sounds positive. During this phase, the stock price can climb at double-digit rates for consecutive trading days, attracting more investors and pushing the share price even higher.

2. Why Market Expectations Push Biotech Stocks Too High Before FDA Approval

Investor expectations tend to accelerate much faster than underlying fundamentals when the drug is reaching FDA final regulatory review. Since most of the investors do not have enough capability to fully understand FDA’s real consideration when viewing company’s phase 3 trial results, they may price in a high probability of approval solely rely on headline news. The investment community often defaults to simplified assumptions such as “strong Phase 3 data means blockbuster potential” or “FDA designation implies approval is virtually guaranteed.” Although these conclusions can be misleading, they drive substantial inflows of capital and intensify the upward momentum of the stock. From this point forward, most investors are not reacting to reasonable examination of the drug approval probability and revenue forecasting of the drug, but to anticipation. As confidence builds, narrative and sentiment begin to outweigh disciplined valuation, which is supported by IQVIA White Paper: How Clinical Trial Results Impact Biopharma Valuations (4).

Even assuming the drug is ultimately approved, a price spike after approval is not guaranteed. Intrinsic value depends on the financial performance of the company rather than regulatory success alone. Many pharmaceutical companies approach the PDUFA date in a strained liquidity position, expecting to conduct equity financing at a higher valuation once approval arrives. However, there remains a long path from approval to revenue generation, including manufacturing, distribution, insurance coverage negotiations and medical system acceptance. All of these require substantial capital. This leaves companies with two common choices: raise capital through large equity offerings, which can cause significant dilution, or enter licensing agreements with other pharmaceutical companies for commercial rights in specific regions, often including East Asia. Either of these decisions can materially impact the stock price and offset the positivity of approval. This financial reality is frequently overlooked by investors and becomes another contributing factor to share prices reaching levels that disconnect from fundamentals before the FDA decision.

3. Objective Drug Valuation Using Revenue Forecasting and DCF Analysis

If market sentiment and anticipation alone are not reliable indicators of value, then a disciplined and systematic framework is required to assess whether a biotech stock is reasonably priced before FDA approval. The most desirable method is to anchor valuation to the drug’s realistic commercial potential rather than speculation. This begins with revenue forecasting. Instead of assuming that a drug with positive Phase 3 data will automatically become a “blockbuster,” a proper projection estimates market size, expected patient population, treatment adoption curves, pricing strategy, reimbursement landscape, and competition from existing or upcoming therapies. These elements are widely recognized as determinants of commercial performance in pharmaceutical launches according to analyses by McKinsey & Company and Deloitte Life Sciences.

Once a realistic revenue trajectory is estimated, the next step is to convert that forecast into value using a discounted cash flow model. Most of the valuation model does not work well on these pharmaceutical companies due to its consistent net losses during its R&D periods. DCF model converts future cash inflow of the drug revenue generated in the third to fifth year and discount it to present value to calculate a fair intrinsic value range in present. A DCF analysis incorporates the impact of approval probability, commercialization cost, capital expenditure, operating margins, and actual revenue generation. This approach aligns with valuation methodologies commonly applied in institutional healthcare equity research according to CFA Institute’s Financial Reporting & Valuation curriculum.

Key Takeaways

Q1: Why can FDA approvals cause stock drops instead of gains?

Because the market sometimes prices in the drug’s commercial potential before the FDA decision, leaving little upside for the actual approval event.

Q2: What causes the stock price to rise during clinical development?

Each clinical and regulatory milestone, such as Phase 2 results, Phase 3 results, FDA designations and PDUFA scheduling, reduces uncertainty and increases expected value, pushing the share price higher.

Q3: Why do biotech stocks become overvalued before PDUFA?

Investor expectations and sentiment may accelerate faster than underlying fundamentals, leading to pricing based on anticipation rather than realistic valuation.

Q4: Why might a stock not surge even after approval?

Approval does not generate immediate revenue. Commercialization requires significant capital, which often forces companies to pursue equity financing or licensing, both of which can weigh on the share price.

Q5: What is the correct way to evaluate a biotech stock before FDA approval?

The most objective approach is to forecast realistic drug revenue and apply a DCF valuation anchored to intrinsic value rather than hype or sentiment.
References

← Back to All Insights

16